Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma - Prognostic significance

被引:24
作者
Michels, JJ
Duigou, F
Marnay, J
Henry-Amar, M
Delozier, T
Denoux, Y
Chasle, J [1 ]
机构
[1] Ctr Francois Baclesse, Dept Pathol, F-14076 Caen 5, France
[2] Ctr Francois Baclesse, Dept Clin Oncol, F-14076 Caen, France
[3] Ctr Francois Baclesse, Dept Clin Res, F-14076 Caen 5, France
关键词
breast; invasive ductal carcinoma; flow cytometry; Ki-67; p53; p21(waf1); cyclin A; S-phase fraction;
D O I
10.1002/cncr.11209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Between January 11, 1991 and January 8, 1992, 104 patients with previously untreated, invasive, primitive breast carcinoma were admitted to the authors' hospital. METHODS. For each patient, flow cytometry DNA analyses on frozen samples and on immunohistochemical staining were performed, including Ki-67, cyclin A, p53, and p21(Waf1) (p21), with assessment of the percentages of positive nuclei were assessed. Correlations with classic clinicopathologic data and survival (overall, metastasis free, or recurrence free) and a multivariate analysis were performed. RESULTS. After a multivariate analysis according to a Cox model that was stratified by age, tumor size, tumor grade, lymph node status, and receptor status, among the factors studied, the presence of p21 was the unique remaining prognostic factor for patients with invasive breast carcinoma. Because of the lack of a correlation between p21 and proliferative factors (Ki-67, S-phase, and cyclin A), the authors combined p21 with those markers and found that, for the different combinations, after statistical analysis, only p21 combined with S-phase or with cyclin A and lymph node status were salient survival prognostic factors. CONCLUSIONS. Immunnhistochemical study of proteins involved in the cell cycle and assessment of proliferative activity using flow cytometric DNA analysis aided the authors in singling out correlations of cyclin A and S-phase, along with p21, with metastasis free survival and overall survival in patients with invasive breast carcinoma. These promising results will require confirmation in a larger series of patients. (C) 2003 American Cancer Society.
引用
收藏
页码:1376 / 1386
页数:11
相关论文
共 135 条
[1]  
Alsner J, 2000, CLIN CANCER RES, V6, P3923
[2]   EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY [J].
ARCHER, SG ;
ELIOPOULOS, A ;
SPANDIDOS, D ;
BARNES, D ;
ELLIS, IO ;
BLAMEY, RW ;
NICHOLSON, RI ;
ROBERTSON, JFR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1259-1266
[3]   What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas? [J].
Arisio, R ;
Sapino, A ;
Cassoni, P ;
Accinelli, G ;
Cuccorese, MC ;
Mano, MP ;
Bussolati, G .
JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (11) :846-850
[4]   IMAGE CYTOMETRIC DNA ANALYSIS IN HUMAN BREAST-CANCER ANALYSIS MAY ADD PROGNOSTIC INFORMATION IN DIPLOID CASES WITH LOW S-PHASE FRACTION BY FLOW-CYTOMETRY [J].
BALDETORP, B ;
FERNO, M ;
FALLENIUS, A ;
FALLENIUSVECCHI, G ;
IDVALL, I ;
OLSSON, H ;
SIGURDSSON, H ;
AKERMAN, M ;
KILLANDER, D .
CYTOMETRY, 1992, 13 (06) :577-585
[5]   Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma [J].
Bánkfalvi, A ;
Tory, K ;
Kemper, M ;
Breukelmann, D ;
Cubick, C ;
Poremba, C ;
Füzesi, L ;
Lellè, RJ ;
Böcker, W .
PATHOLOGY RESEARCH AND PRACTICE, 2000, 196 (07) :489-501
[6]   p21(WAF1) immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival [J].
Barbareschi, M ;
Caffo, O ;
Doglioni, C ;
Fina, P ;
Marchetti, A ;
Buttitta, F ;
Leek, R ;
Morelli, L ;
Leonardi, E ;
Bevilacqua, G ;
DallaPalma, P ;
Harris, AL .
BRITISH JOURNAL OF CANCER, 1996, 74 (02) :208-215
[7]  
Bast RC, 1996, J CLIN ONCOL, V14, P2843
[8]  
Bast RC, 1998, J CLIN ONCOL, V16, P793
[9]  
Bebenek M, 1998, ANTICANCER RES, V18, P619
[10]  
Bergers E, 1996, CANCER, V77, P2258